Taysha Gene Therapies Inc (NASDAQ: TSHA) — Perfil da empresa, notícias e dados financeiros
Taysha Gene Therapies focuses on developing gene therapies for rare diseases affecting the central nervous system.
Taysha Gene Therapies Inc
Taysha Gene Therapies (NASDAQ:TSHA) is focused on the development and commercialization of innovative gene therapy treatments for rare and severe diseases, primarily targeting the central nervous system. With a robust pipeline of gene therapy candidates, Taysha aims to tackle genetic disorders that currently have limited or no treatment options. The company's objectives include advancing its clinical programs to bring transformative therapies to patients, leveraging cutting-edge technology to enhance gene therapy delivery, and expanding its research to cover more diseases. Taysha is deeply committed to addressing the unmet needs of patients and families affected by rare genetic conditions, striving to improve quality of life through scientific breakthroughs.
Resumo
Operações
Produtos e/ou serviços de Taysha Gene Therapies Inc
- Gene therapy for GM2 Gangliosidosis, targeting the root genetic causes of Tay-Sachs and Sandhoff diseases.
- AAV9-based Rett syndrome treatment, focusing on reversing the neurological disorder symptoms.
- Gene therapy for Giant Axonal Neuropathy, aimed at restoring normal function of the nervous system.
- Development of treatments for SLC6A1 haploinsufficiency disorder, with the potential to correct related epilepsy and neurodevelopmental deficits.
- Gene therapy project for SURF1-associated Leigh Syndrome, targeting mitochondrial dysfunction.
- Program targeting Charcot-Marie-Tooth Disease with gene therapy, aiming to address peripheral nerve damage.
equipe executiva do Taysha Gene Therapies Inc
- Sean P. NolanCEO & Chairman
- Sukumar NagendranPresident, Head of Research & Development and Director
- Kamran AlamCFO & Corporate Secretary
- Hayleigh CollinsDirector of Corporate Communications & Investor Relations
- Michael B. JohannesenChief Legal Officer & Corporate Secretary
- Frederick PorterChief of Staff & Technical Operations Officer
- Emily McGinnisChief Patient & External Affairs Officer
- Sean McAuliffeChief Business Officer
- Steven GrayChief Scientific Advisor of UT Southwestern Gene Therapy Program
- Berge MinassianChief Medical Advisor of UT Southwestern Gene Therapy Program
Principais indicadores financeiros
Resultados divulgados pela Taysha Gene Therapies Inc, em USD.
- Cap. de mercado
- 1,4 bi
- Receita (TTM)
- 5,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 9,8 mi | -110,5 mi | -109 mi | |
| 8,3 mi | -91,5 mi | -89,3 mi | |
| 15,5 mi | -72,4 mi | -111,6 mi | |
| 2,5 mi | -126 mi | -166 mi |